Back to top

vaccines: Archive

Zacks Equity Research

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

PFENegative Net Change HRTXNo Net Change MRNSPositive Net Change ARQTNegative Net Change

Sundeep Ganoria

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change CVACPositive Net Change

Zacks Equity Research

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.

SNYNegative Net Change PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

SNYNegative Net Change PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKNegative Net Change MRNAPositive Net Change LGNDNegative Net Change ANIPNegative Net Change

Zacks Equity Research

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

GSKNegative Net Change JNJNegative Net Change ANIPNegative Net Change VIRNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNNegative Net Change PFENegative Net Change NVOPositive Net Change AMGNNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

MRKNegative Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change